DXCM — DexCom, Inc.

Summary of DexCom, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q1 2026 revenue was $1.19 billion, a 15% increase from $1.04 billion in Q1 2025. Organic revenue growth was 12%.
• U.S. Revenue: $832 million, up 11% year-over-year.
• International Revenue: $360 million, reflecting a 26% increase, with organic growth of 17%.
• Gross Profit: $757.4 million (63.5% of revenue), up from 57.5% in Q1 2025.
• Operating Income: $264.4 million (22.2% of revenue), compared to $143.1 million (13.8%) in the prior year.
• Net Income: $216.3 million, or $0.56 per share, representing a 75% increase year-over-year.
• Cash Position: Approximately $2.4 billion in cash and cash equivalents, up over $400 million from year-end 2025.

2. Strategic Updates and Business Highlights

• Product Launches: Successful rollout of the DexCom G7 15-day system, which has received positive feedback for its accuracy and longer wear time.
• Market Expansion: Significant share gains in the type 2 diabetes segment, particularly among non-insulin users, with new coverage from Prime Therapeutics expected to add over 1 million lives.
• Clinical Evidence: Ongoing randomized control trial for type 2 non-insulin users, with results expected to bolster coverage discussions with payers.
• International Growth: Strong performance in international markets, particularly in France and Canada, attributed to expanded access and reimbursement wins.

3. Forward Guidance and Outlook

• Revenue Guidance: Reaffirmed full-year revenue guidance of $5.16 billion to $5.20 billion, indicating growth of 11% to 13%.
• Margin Guidance: Maintained gross profit margin guidance at 63% to 64%, while increasing operating profit margin guidance to 23% to 23.5% and adjusted EBITDA margin to 31% to 31.5%.
• Patient Growth: Anticipated continued growth in new patient starts, with nearly 50% of the existing base expected to transition to the new 15-day product by year-end.

4. Bad News, Challenges, or Points of Concern

• Market Growth: Concerns about slower growth in the U.S. CGM market due to a lack of major coverage expansions or new indications, as noted by competitors.
• Geopolitical Risks: Uncertainties related to fuel prices and shipping routes could impact gross margins, with a potential headwind of 50 to 100 basis points factored into guidance.
• Competitive Pressures: The company faces challenges from competitors in a market that may be experiencing a slowdown in growth.

5. Notable Q&A Insights

• Market Dynamics: Management expressed confidence in the U.S. market's potential, citing only 30% penetration among covered lives and ongoing efforts to increase awareness and coverage.
• Type 2 Non-Insulin Market: The upcoming RCT results are expected to be significant for future growth, with management emphasizing the importance of expanding access to this population.
• Sales Strategy: The salesforce is increasingly targeting primary care physicians to enhance coverage awareness and prescription writing for CGM.
• Cash Utilization: The company is exploring various capital allocation opportunities, including potential M&A and share buybacks, while maintaining a strong free cash flow profile.

Overall, DexCom reported strong financial performance in Q1 2026, driven by product innovation and market expansion, while navigating challenges related to market growth and geopolitical risks.